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Abstract 
Migraine is a common neurological disease with a genetic basis affecting approximately 12 % of the 
population. Pain during a migraine attack is associated with activation of the trigeminal nerve system 
, which carries pain signals from the meninges and the blood vessels infusing the meninges to the 
trigeminal nucleus in the brain stem. The release of inflammatory mediators following cortical 
spreading depression (CSD) may further promote and sustain the activation and sensitisation of 
meningeal nociceptors, inducing the persistent throbbing headache characterised in migraine.  
Lymphotoxin α (LTA) is a cytokine secreted by lymphocytes and is a member of the tumour necrosis 
factor (TNF) family. Genetic variation with the TNF and LTA genes may contribute to threshold brain 
excitability, propagation of neuronal hyperexcitability and thus initiation and maintenance of a 
migraine attack. Three LTA variants rs2009658, rs2844482 and rs2229094 were identified in a recent 
pGWAS study conducted in the Norfolk Island population as being potentially implicated in migraine 
with nominally significant p values of p=0.0093, p=0.0088 and p=0.033 respectively. To determine 
whether these SNPs played a role in migraine in a general outbred population these SNPs were 
gentoyped in a large case control Australian Caucasian population and tested for association with 
migraine. All three SNPs showed no association in our cohort (p>0.05). Validation of GWAS data in 
independent case-controls cohorts is essential to establish risk validity within specific population 
groups. The importance of cytokines in modulating neural inflammation and pain threshold in 
addition to other studies showing associations between TNF-α and SNPs in the LTA gene with 
migraine, suggests that LTA could be an important factor contributing to migraine. Although the 
present study did not support a role for the tested LTA variants in migraine, investigation of other 
variants within the LTA gene are still warranted. 
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Introduction 
Migraine is a common neurological disorder characterized by debilitating head pain and an 
assortment of additional symptoms, which can include nausea, emesis, photophobia, phonophobia 
and occasionally visual sensory disturbances. It affects approximately 12% of the population with 
affected individuals being predominantly female (1). Migraine results in a significant cost to the 
economy each year mostly because of lost productivity in the work place, but it also has a large 
personal impact on sufferers. According to classification criteria of the International Headache 
Society migraine is sub-divided into two major categories namely migraine with (MA) and migraine 
without (MO) aura (2).  Migraine is a complex disease caused by interplay between predisposing 
genetic variants and environmental factors (3-5). Genes involved in neurological, vascular or 
hormonal pathways have all been implicated to play a role in predisposition towards developing 
migraine (6-8). 
The neurovascular hypothesis states that migraine is caused through trigeminal nerve activation and 
that vasodilatation is a secondary response (9, 10). The trigeminovascular system consists of afferent 
fibres which innervate the proximal parts of the large cerebral vessels, pial vessels, large venous 
sinuses and the dura mater (11). When activated by a stimulus or decreased threshold resulting in 
cortical spreading depression (CSD), nociceptive information is relayed via the trigeminal nerves to 
the trigeminal nucleus and then to the cortical pain areas via the thalamus. This in turn stimulates 
the release of powerful vasoactive peptides resulting in dilation of cerebral and dural blood vessels. 
Dural vasodilatation is mediated via the release of calcitonin gene-related peptide (CGRP), 
neurokinin A and substance P (12).  
The release of inflammatory mediators such as cytokines and mast cells following CSD, may further 
promote and sustain the activation and sensitisation of meningeal nociceptors, inducing the 
persistent throbbing headache characterised in migraine (11). Mast cells release proteases and 
inflammatory mediators, including tumour necrosis factor (TNF)-α and interleukin (IL-6) upon 
exposure to sensory neuropeptides (10). The tumour necrosis factor (TNF) gene cluster, made up of 
TNF, lymphotoxin α (LTA) and lymphotoxin β (LTB) has been implicated by a number of studies to 
influence the intensity and duration of local inflammation. It is thought that sterile inflammation 
mediated by LTA and TNF contributes to threshold brain excitability, propagation of neuronal 
hyperexcitability and thus initiation and maintenance of a migraine attack (13, 14). 
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As discussed previously, LTA belongs to the TNF locus, depicted in Figure 1. This gene locus is located 
on the short arm of chromosome 6 and is part of the Major Histone Compatibility (MHC) class III 
region. The LTA gene consists of 4 exons and 3 introns which undergo alternative splicing to produce 
at least 7 isoforms (15). A previous pGWAS study genotyped 620 901 SNPs in 76 migraine affected 
cases and 209 non-migraine individuals in the Norfolk Island (NI) population. Association testing 
using measured genotype analysis identified a number of SNPs located within the LTA gene 
significantly associated with migraine in the NI population (16). Norfolk Island is a self-governing 
Australian territory located in the South Pacific Ocean between New Caledonia, New Zealand, and 
Australia along the Norfolk Ridge. The majority of current, permanent residents are descended from 
9 Isle of Man (Caucasian), ‘Bounty’ Mutineers and 6 Tahitian (Polynesian) women, and 2 European 
Whalers (Male) who joined the small colony in the early 19th century (17). Population structure, 
pedigree verification and CVD-risk trait molecular genetics in addition to migraine molecular genetics 
have been well characterised in the Norfolk Island population (17-21). 
 The aim of this study was to determine if the LTA SNPs identified in the pGWAS play a role in 
migraine in a general outbred population. The NI pGWAS identified five LTA SNPs namely rs2009658, 
rs2844482, rs1800683, rs2229094, and rs1041981 with strong association with migraine 
susceptibility, summarised in Table 1 (22). A number of other studies have also investigated variation 
within the LTA gene and possible associations with migraine. Of particular interest was a study 
conducted in a Korean population, where rs2844482 was found to be significantly (p=0.0003) 
associated with migraine (23). Here, we examined three of these SNPs, rs2009658, rs2844482 and 
rs2229094 in a large Australian case control cohort for association with migraine. 
Materials and Methods 
Norfolk Island pGWAS 
Blood samples along with participant phenotype information was collected as described by Bellis et 
al 2005 (20). Briefly, following DNA extraction from blood samples using salting out (24), a sub-
sample of 285 related individuals (135 males; 150 females) descended from the population founders 
were genotyped for 620,901 genome wide markers (mean spacing 4.7kb) on an Illumina Infinium 
High Density (HD) Human610-Quad DNA analysis BeadChip v1. The population included 76 migraine 
cases (22 males; 54 females). Association between SNPs and migraine was tested using measured 
genotype analysis (25) embedded in a variance components-based linkage model (20) and 
annotated using the Whole Genome Association Study Viewer (WAGViewer) program 
(http://people.genome.duke.edu/~dg48/WGAViewer/) and NCBI Build 37.1. 
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 Variants within the genomic sequence of positive migraine candidate genes identified through a 
literature review were selected and annotated using WAGViewer. Locality and statistical information 
were compiled. Haplotypic assessment of potential migraine susceptibility genes was undertaken in 
the Norfolk pedigree using the program Haploview.  A local type I error of α = 0.05 was applied. 
Genome-wide Bonferroni adjustment was not required to protect against type I error inflation as the 
application of selection criteria for candidate genes negates the global null. Five SNPs within the LTA 
gene region were found to be significantly associated with migraine. Given the importance that 
cytokines are known to have in modulating neural inflammation, three of these SNPs were selected 
for replication in a large Australian Caucasian migraine case-control for genotypic analyses.  
LTA Genotyping 
Sample Selection 
Migraine cases and controls were recruited for the local South East Queensland region as previously 
described (26). They were all of Caucasian origin, and diagnosed as having MA or MO based on 
criteria specified by the International Headache Society. An unaffected control group with no family 
history of migraine was matched for age (+/- 5 years), sex and ethnicity. Blood samples obtained 
from patients were collected through the Genomics Research Centre clinic.  
Molecular Analysis 
rs2009658 
Amplification of a 302bp target site in the LTA gene was carried out by PCR using forward (5’- 
CTGGGGAGAGAAGTGGTCTG-3’) and reverse (5’-TTGATGGGGATTTGGTTTGT-3’) primers. The reaction 
mixture contained buffer, 1.75 mM of MgCl2, 200 µM of dNTPs, 100nM of each primer, 1 unit of 
GoTaq® Flexi DNA polymerase (Promega) and 40 ng of genomic DNA in a total reaction volume of 20 
µl. PCR was performed in a 96-well thermocycler (Applied Biosystems) with the following conditions: 
an initial denaturation at 95°C for 10 mins was followed by 35 cycles of denaturation at 95°C for 1 
min, annealing at 56°C for 1 min and extension at 72°C for 1 min and a final extension at 72°C for 7 
mins. Genotyping was done using restriction fragment length polymorphism (RFLP) analysis. The 
amplicon product was digested with NlaIII which cuts the recognition site CATG. The RFLP reaction 
mixture contained 8 µl of PCR product, 6 units of NlaIII, 1.2 µl of 10 X reaction buffer in a total 
volume of 12 µl. The digest was incubated at 37°C for 6 hours. Digested products were then 
separated by electrophoresis on a 4 % agarose gel dyed with ethidium bromide for 1 hr 10 min at 70 
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V. Different fragment lengths produced by RFLP were used to identify genotypes.  A total of 296 
cases and 304 cases were genotyped. 
rs2229094 
Foward (5’-TCTCTTTCTCTGCAGGTTCTC-3’) and reverse (5’-CCCAGAAGGAGGAGGTGTAG-3’) primers 
were used to amplify a 92 base pair region of the LTA gene containing a single SNP (rs2229094). High 
resolution melt analysis (HRM) was then used to genotype 293 case and 301 control samples. 
Initially the Rotor-Gene™ 6000 was used, but later on the assay was transferred to the 7900HT Fast 
Real-Time PCR system using the same reaction volume and reagent concentrations. Amplification by 
PCR followed by a dissociation step was carried out consecutively. The reaction mixture contained 
1.5 mM of MgCl2, 300 nM of each primer, 200 µM dNTPs, 1.5 µM of SYTO9, 0.375 Units of HotStart 
DNA Taq polymerase and 40ng DNA template in a final reaction volume of 15uL. Cycling conditions 
were as follows: activation at 94°C for 5 minutes, followed by 45 cycles of denaturation at 95°C for 5 
seconds and annealing at 58°C for 10 seconds. The dissociation step was optimized to a melt range 
of 77°C to 87°C, with a ramp rate of 1% or a 0.1°C temperature increase per second.  Products were 
run on a 2% agarose gel for confirmation of amplification. Genotypes were determined using the 
Rotor-Gene™ 6000 or MeltDoctor software. Positive controls (illustrated in Figure 3) were confirmed 
through Sanger sequencing. A total of 293 cases and 301 controls were genotyped 
rs2844482 
A custom designed TaqMan assay was used to genotype 268 case and 295 control samples.   Custom 
designed assay AHQJH3T made use of forward (5’-CCAAAGAAGGGACAGTCAATTCAGA-3’) and 
reverse (5’-GGGCCTCCAGCTCACA-3’) primers with differentially labelled reporter sequences 1 (5’-
CTGCTCAACTACCTCCT-3’) and reporter sequence 2 (5’-TGCTCAACCACCTCCT-3’). The reporter 
sequences differed by a single base pair, with reporter sequence 1 containing a T while reporter 
sequence 2 contained a C.  Reporter sequence 1 was labelled with VIC dye and reporter sequence 2 
with FAM, which upon laser excitation allowed the 7900HT Fast Real-Time PCR system to determine 
which allele was present. Heterozygous samples would emit a signal for both dyes. Each reaction 
contained the following: 5uL Universal PCR mix (2X), 0.25uL custom probe primer mix (10X) and 1uL 
of DNA template at 20ng/uL in a final reaction volume of 10uL. Positive control samples were set up 
on each plate and validated by pyrosequencing (Qiagen). 
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Statistical Analysis 
The gene counting method was used to determine the allele frequencies in both case and control 
populations. Hardy-Weinberg Equilibrium (HWE) was used to test for deviation between observed 
and expected allele frequencies in both the case and control populations (27). A Chi Square analysis 
was performed to test for significant allele frequency differences between the case and control 
populations and to determine whether alleles were significantly associated with migraine (α=0.05). 
Results were further analysed according to migraine subtype as classified by the International 
Headache Society. The odds ratio at a 95% confidence interval was calculated as an indication of 
disease risk. 
Results 
rs2009658 
Both the case and control population were in HWE. When the Chi-square test was used to compare 
genotype differences between cases and controls no significant differences were found between 
cases and control genotype frequencies (p = 0.49). Upon subsequent analysis according to migraine 
subtype no significant association was found with MA (p = 0.56) or MO (p = 0.11). When allele 
frequencies were compared between the case and control population no significant association was 
found (p = 0.50).  In addition, no significant association was found with migraine subtypes MA (p = 
0.64) or MO (p = 0.55). Results are summarised in Table 2. 
rs2229094 
Both the case and control population were in HWE. When the Chi-square test was used to compare 
genotype differences between cases and controls no significant differences were found between 
cases and control genotype frequencies (p = 0.54). Upon subsequent analysis according to migraine 
subtype no significant association was found with MA (p = 0.74) or MO (p = 0.50). Results are 
summarised in Table 2. No significant difference was found in the allele frequencies between the 
cases and the controls (p = 0.45). MAs and MOs were also separately compared to the controls but 
this also revealed no significant difference in the allele frequencies (MA vs controls: p = 0.55, MO vs 
controls: p = 0.71).  
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rs2844482 
The case and control populations were found to be in HWE. Genotyping results showed no 
significant association with migraine with a p value upon Chi Square analysis of p=0.4001. These 
results are summarized in Table 2. When analysis according to migraine subtype was performed no 
significant association was found between the C>T change and MA (p=0.4450). Migraine without 
aura (MO) also showed no significant association (p=0.1270).  
Discussion 
Five SNPs situated within the LTA gene were found to be significantly associated with migraine in a 
recent pGWAS study conducted on the genetic isolate Norfolk Island population (28).  Given the role 
that sterile inflammation is likely to play in propagation of a migraine attack, it was hypothesized 
that significant association was found due to the role that inflammatory mediators, including LTA, 
are postulated to play in the inflammatory stage of a migraine attack. It is possible that variants 
within the LTA gene modulate the expression of this inflammatory mediator and thus upon sensory 
neuropeptide exposure alter the intensity and duration of local inflammation. This could in turn 
lower threshold brain excitability and thus contribute to initiation and also maintenance of a 
migraine attack. In order to further test this hypothesis and the potential role that LTA variants may 
play in migraine susceptibility, this study aimed to replicate the previously identified associations in 
an outbred population. Three SNPs were selected according to function and significance to be 
genotyped in a large case-control cohort. 
The first SNP rs2009658 is a C>G change located upstream of the LTA gene in chromosome position 
31538244 (NCBI build 37.2). The minor allele frequency in the European population is approximately 
0.16 (29). Other diseases that rs2009658 has already been associated with include Behcet syndrome, 
which is a chronic inflammatory disease involving small blood vessels (30, 31). Despite physiological 
function and evidence already found implicating a pathogenic role in inflammation, this SNP did not 
show any association with migraine in the Australian Caucasian population tested.  
The second SNP investigated, rs2229094 is a T>C change located in the second exon of the LTA gene 
in chromosome position 31540556 (NCBI build 37.2). The change causes a non synonymous 
mutation (Cys13Arg)(29). The minor allele frequency in the European population is 0.25. Like 
rs2009658, rs2229094 is also associated with Behcet syndrome (31) but is not associated with 
migraine in our cohort. When investigated in our Australian Caucasian population, rs2844482 also 
showed no association with migraine. These findings are conflicting to the previously mentioned 
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study conducted in a Korean population, where highly significant association was found between 
migraine and rs2844482 (32). These results also differ from the significant associations found in the 
previously conducted pGWAS study in the genetically isolated Norfolk Island population. 
It is possible that previous significant findings were not replicated in our Australian outbred 
population due to differences in population structure and ethnicity. The Norfolk Island cohort is a 
genetically isolated population and therefore allele frequencies are likely to be unique in comparison 
to other population groups. The lack of significance found between rs2844482 and migraine in 
comparison with the Korean study is also likely due to ethnicity. Given the role that cytokines are 
known to play in inflammation it may be possible that other variants with the LTA gene affect 
migraine susceptibility. It is also possible that other pro-inflammatory cytokines are involved in 
mediation of migraine attacks and it would be valuable to investigate some of these genes in 
relation to migraine susceptibility. 
Conclusion 
The SNPs examined previously identified to be positively associated with migraine susceptibility in a 
previous pGWAS conducted in the Norfolk Island population were not found to be significant when 
genotyped in an outbred population. The three SNPs investigated were not associated with migraine 
in our Australian Caucasian case-control population. Both rs2009658 and rs2229094 produced p 
values well above the significance threshold. The third SNP investigated, rs2844482 also showed no 
association with either MA or MO. It is still plausible that LTA plays a role in migraine susceptibility 
and it would be valuable to investigate other variants within the gene along with other inflammatory 
mediating genes. Cytokines are produced in the healthy brain and play a role both in normal 
neuronal function and in mediating neural inflammation (33).Cytokines are important mediators of 
sterile inflammation and  have been shown to induce head pain. Plasma levels of TNF-α, a pro-
inflammatory cytokine, have been reported to increase during a migraine attack (34). As LTA is 
closely linked with TNF-α, it too could play a role in the initiation and maintenance of a migraine 
attack.  
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Figure 1(35): Schematic diagram depicting the TNF cluster 
 
 
 
 
Figure 2: Melt curves of positive controls used for genotyping by HRM (rs2229094) 
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Table2: Allele and genotype frequency distributions amongst case-control population 
Case-Control Cohort  
 Allele (%) Genotype (%) 
Marker C (%) G (%) P value 
CC (%) CG (%) GG (%) 
 
P Value 
rs2009658        
Cases 489 (82.7) 103 (17.3) p = 0.50 200 (67.6) 89 (30) 7 (2.4) p = 0.49 
MA 406 (82.5) 88 (17.5) p = 0.64 165 (66.8) 76 (30.8) 6 (2.4) p = 0.56 
MO 77 (83.3) 15 (16.7) p = 0.55 32 (69.6) 13 (28.2) 1 (2.2) p = 0.11 
Controls 493 
(0.811) 
115 
(0.189) 
 200 (65.8) 93 (30.6) 11 (3.6)  
rs2229094 T (%) C (%) P Value TT (%) CT (%) CC (%) P Value 
Cases 430 (73.0) 156 (27.0) p = 0.45 162 (55.3) 106 (36.2) 25 (8.5) p = 0.54 
MA 358 (73.0) 132 (27.0) p = 0.55 133 (54.3) 92 (37.5) 20 (8.2) p = 0.74 
MO 66 (73.0) 24 (27.0) p = 0.71 26 (57.8) 14 (31.1) 5 (11.1) p = 0.50 
Controls 430 (71.0) 172 (29.0)  154 (51.2) 122 (40.5) 25 (8.3)  
rs2844482 C (%) T (%) P value 
CC (%) CT (%) TT (%) 
 
P Value 
Cases 341 (63.6 195 (36.4) p = 
0.4001 
123 (45.9) 95 (35.4) 50 (18.7) p = 0.1300 
MA 349 (63.5) 105(36.5) p = 
0.4450 
102(45.9) 78(35.1) 42 (19.0) p = 0.1401 
MO 60(70.0) 18(30.0) p = 
0.1270 
21 (52.5) 14(35.0) 5 (12.5) p = 0.2795 
Controls 361 (61.2) 229 (38.8)  116(39.3) 129 (43.7) 50(17.0)  
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Table 1: LTA SNPs associated with migraine in the Norfolk Island pedigree  
 
 
Locus Gene  
 
No. 
SNPs 
in 
Gene 
NCBI dbSNP  
Ref No. 
NCBI Build 
37.1 
Position 
(BP) 
Function 
 
Minor/ 
Major 
Allele 
MAF 
 
Beta* 
 
P-Value 
 
       6p21.3        LTA 
   
   14      rs2009658 
      
31538244      Upstream      G/C 
 
0.211 
 
0.409 
 
0.0093 
  
 
     rs2844482 
      
31539767      Upstream      A/G 
 
0.214 
 
0.410 
 
0.0088 
   
     rs1800683 
      
31540071      5prime UTR      A/G 
 
0.418 
 
-0271 
 
0.027 
   
     rs2229094 
      
31540556      Non-Synonymous           C/T 
 
0.270 
 
0.302 
 
0.033 
   
     rs1041981 
      
31540784      Non-Synonymous       A/C 
 
0.417 
 
-0.271 
 
0.027 
